PortfoliosLab logoPortfoliosLab logo
ANRO vs. AYTU
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ANRO vs. AYTU - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Alto Neuroscience, Inc (ANRO) and Aytu BioPharma, Inc. (AYTU). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ANRO achieves a 28.82% return, which is significantly higher than AYTU's -13.46% return.


ANRO

1D
0.84%
1M
8.06%
YTD
28.82%
6M
14.42%
1Y
919.11%
3Y*
5Y*
10Y*

AYTU

1D
-2.60%
1M
2.74%
YTD
-13.46%
6M
-15.09%
1Y
12.50%
3Y*
10.45%
5Y*
-54.31%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

ANRO vs. AYTU - Yearly Performance Comparison


2026 (YTD)20252024
ANRO
Alto Neuroscience, Inc
28.82%320.80%-80.77%
AYTU
Aytu BioPharma, Inc.
-13.46%52.94%-36.33%

Correlation

The correlation between ANRO and AYTU is 0.20, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.20

Correlation (All Time)
Calculated using the full available price history since Feb 2, 2024

0.17

Fundamentals

Market Cap

ANRO:

$754.24M

AYTU:

$23.65M

EPS

ANRO:

-$2.50

AYTU:

-$2.91

PB Ratio

ANRO:

3.10

AYTU:

0.67

Total Revenue (TTM)

ANRO:

$0.00

AYTU:

$56.60M

Gross Profit (TTM)

ANRO:

-$421.00K

AYTU:

$36.14M

EBITDA (TTM)

ANRO:

-$74.36M

AYTU:

-$27.34M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ANRO vs. AYTU — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ANRO
ANRO Risk / Return Rank: 9999
Overall Rank
ANRO Sharpe Ratio Rank: 9999
Sharpe Ratio Rank
ANRO Sortino Ratio Rank: 9898
Sortino Ratio Rank
ANRO Omega Ratio Rank: 9898
Omega Ratio Rank
ANRO Calmar Ratio Rank: 100100
Calmar Ratio Rank
ANRO Martin Ratio Rank: 100100
Martin Ratio Rank

AYTU
AYTU Risk / Return Rank: 5050
Overall Rank
AYTU Sharpe Ratio Rank: 5050
Sharpe Ratio Rank
AYTU Sortino Ratio Rank: 4848
Sortino Ratio Rank
AYTU Omega Ratio Rank: 4848
Omega Ratio Rank
AYTU Calmar Ratio Rank: 5151
Calmar Ratio Rank
AYTU Martin Ratio Rank: 5252
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ANRO vs. AYTU - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Alto Neuroscience, Inc (ANRO) and Aytu BioPharma, Inc. (AYTU). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


ANROAYTUDifference
Sharpe ratioReturn per unit of total volatility

+7.00

Sortino ratioReturn per unit of downside risk

+4.94

Omega ratioGain probability vs. loss probability

1.72

1.09

+0.63

Calmar ratioReturn relative to maximum drawdown

27.15

0.35

+26.80

Martin ratioReturn relative to average drawdown

70.91

0.81

+70.10

ANRO vs. AYTU - Sharpe Ratio Comparison

The current ANRO Sharpe Ratio is 7.23, which is higher than the AYTU Sharpe Ratio of 0.23. The chart below compares the historical Sharpe Ratios of ANRO and AYTU, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

ANRO vs. AYTU - Drawdown Comparison

The maximum ANRO drawdown since its inception was -91.82%, smaller than the maximum AYTU drawdown of -100.00%. Use the drawdown chart below to compare losses from any high point for ANRO and AYTU.


Loading charts...

Drawdown Indicators


ANROAYTUDifference

Max Drawdown

Largest peak-to-trough decline

-91.82%

-100.00%

+8.18%

Max Drawdown (1Y)

Largest decline over 1 year

-34.20%

-35.47%

+1.27%

Max Drawdown (3Y)

Largest decline over 3 years

-70.24%

Max Drawdown (5Y)

Largest decline over 5 years

-99.09%

Current Drawdown

Current decline from peak

-17.28%

-100.00%

+82.72%

Average Drawdown

Average peak-to-trough decline

-53.30%

-95.27%

+41.97%

Ulcer Index

Depth and duration of drawdowns from previous peaks

13.07%

15.55%

-2.48%

Volatility

ANRO vs. AYTU - Volatility Comparison

Alto Neuroscience, Inc (ANRO) has a higher volatility of 24.19% compared to Aytu BioPharma, Inc. (AYTU) at 16.13%. This indicates that ANRO's price experiences larger fluctuations and is considered to be riskier than AYTU based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ANROAYTUDifference

Volatility (1M)

Calculated over the trailing 1-month period

24.19%

16.13%

+8.06%

Volatility (6M)

Calculated over the trailing 6-month period

54.92%

34.71%

+20.21%

Volatility (1Y)

Calculated over the trailing 1-year period

128.77%

55.79%

+72.98%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

115.37%

85.38%

+29.99%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

115.37%

187.85%

-72.48%

Dividends

ANRO vs. AYTU - Dividend Comparison

Neither ANRO nor AYTU has paid dividends to shareholders.


Tickers have no history of dividend payments

Financials

ANRO vs. AYTU - Financials Comparison

This section allows you to compare key financial metrics between Alto Neuroscience, Inc and Aytu BioPharma, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00M10.00M15.00M20.00M25.00M30.00M35.00MJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober2025AprilJulyOctober20260
12.41M
(ANRO) Total Revenue
(AYTU) Total Revenue
Values in USD except per share items

Frequently Asked Questions


ANRO and AYTU have a correlation of 0.20, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ANRO has higher volatility (24.19%) compared to AYTU (16.13%). In terms of maximum drawdown, ANRO dropped -91.82% vs AYTU's -100.00%.

ANRO currently has the higher Sharpe Ratio (7.23 vs 0.23), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ANRO and AYTU

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer